Medigene NA O.N. (DE:MDG1k) has announced that it has expanded its TCR platform technology with the grant of a US patent focused on a method for identifying T-cell antigens. This demonstrates Medigene’s continued advancement of its TCR technology, including providing a new source for potential TCR candidates and establishing a more efficient method for identifying tumour-specific antigens. We maintain our rNPV-based valuation at €214m, or €10.8 per share, with upside expected as it executes its clinical strategy.
Expansion of TCR platform technology – US patent
Medigene has expanded its TCR platform technology with the grant of a US patent, which claims a method for the identification of antigens recognised by CD4+ T-cells, including tumour-infiltrating CD4+ T-cells. The patent has a significant period of time to expiry (2030) and is important to Medigene as it offers an effective additional source for potential TCR candidates. It also enables the identification of patient-specific neoantigens seen by CD4+ cells. Neoantigens are potentially good targets for cancer immunotherapy as they are specifically expressed in the tumour, which potentially enables therapies to be specifically targeted.
To read the entire report Please click on the pdf File Below